Pharmacy carve-outs can hide more cost than they save
Rising drug spend has pushed many employers toward carving pharmacy benefits away from medical coverage, especially as specialty and chronic-disease therapies take a larger share of the budget. Pharmaceutical Strategies Group’s 2025 Artemetrx report placed per-member-per-year specialty drug costs at $1,641 in 2024, up from $1,333 in 2023. The pressure is obvious. Specialty drugs already consume a disproportionate share of pharmacy spending, and every increase forces plan sponsors to look for savings somewhere else.
The problem is that a benefit design built to isolate drug costs can also isolate the clinical signals that explain them. A refill gap may look like a pharmacy problem on paper, yet the real driver may be an unaffordable copay, worsening disease control, or a missed opportunity to adjust therapy before the patient shows up in the emergency department. When pharmacy and medical data sit in separate systems, the people managing one side of care may never see the warning signs on the other.
Integrated claims data changes what care teams can see
Employer groups that keep medical and pharmacy benefits under one roof gain a broader view of utilization, adherence, and risk. In integrated plans, clinical teams can connect a missed refill with rising glucose values, a new specialty medication with the diagnosis that prompted it, or a repeated emergency room pattern with a chronic illness that has drifted out of control. The practical effect is earlier intervention, and earlier intervention often means avoiding the kind of acute event that drives the largest bills.
The figures cited in this material point to a consistent pattern. Employer groups with integrated medical and pharmacy coverage see 8% lower hospital inpatient costs, 2% to 3% fewer emergency room visits, and 10% to 12% lower emergency room costs compared with groups using separated benefits. They also see a 13% to 14% lower incidence of high-cost claimants, while chronically ill members on integrated plans cost 9% to 10% less to cover. Across employer accounts, total medical expenses run roughly 5% to 6% lower than they do under non-integrated plans.
A one-sentence reality check: the costliest claim is often the one that was never visible when the first refill was missed.
Prior authorization can move faster when the medical record is attached
Integration is not only about cost containment. It also changes the administrative burden that surrounds treatment decisions. Blue Cross Blue Shield of Massachusetts data show that medical claims can be used to automatically validate pharmacy prior authorizations through SmartPA, allowing 32% of eligible prescription claims to be approved instantly at the point of sale. In a single year, about 47,000 members bypassed the traditional manual prior authorization process, eliminating 47,000 redundant reviews for local healthcare providers.
This kind of automation matters because prior authorization delays can interrupt treatment before a patient ever receives the medication. When the medical diagnosis is already documented in the claims record, a payer does not need to ask for the same information twice. The result is a cleaner workflow for clinicians and a faster path to therapy for patients who already meet coverage criteria.
One member’s medication bill dropped from more than $350 to zero
The clearest case for connected benefits comes from direct care coordination. In one Blue Cross Blue Shield of Massachusetts example, the plan could see both medical and pharmacy claims for a member who was not filling prescriptions and was showing a pattern of high emergency room use. The medical side alone did not reveal the medication problem. Once the team looked across both data streams, it became clear that the member was struggling with multiple copays at once.
Working from the combined record, the care team identified an alternative that consolidated the prescriptions into a single therapy and reduced the member’s out-of-pocket drug cost to $0 per month. Her monthly medication spend fell from more than $350 to zero, and the expensive emergency room visits dropped as well. In a setting where adherence often breaks down because of cost rather than refusal, lowering the monthly burden can be the difference between stable disease control and repeated acute care.
Waste is easier to find when both sides of the claim sit together
A shared data set also supports a dedicated pharmacist team that can look for waste, duplication, and mismatched utilization across the whole plan. Claims that appear routine in isolation can look different when medical and pharmacy records are reviewed side by side. A prescription without a corresponding diagnosis, a billing pattern that emerges only after both files are compared, or a medication trend that does not match the clinical history can all become visible only in an integrated system.
Because those savings are recovered inside the plan, they can be redirected into keeping coverage affordable rather than being lost to fragmented administration. The financial argument is straightforward, but the clinical argument is stronger. Better visibility allows earlier contact with members, more targeted medication decisions, and fewer downstream events that are far more expensive than the drug spend that triggered them.
The tradeoff for employers is visibility versus fragmentation
Carve-outs can look disciplined because they separate a large bill into a standalone management lane. Yet that separation can make the total cost of care harder to track until a hospitalization or emergency visit appears months later. Integrated coverage does not eliminate drug spending, and it does not make every case simpler. It does, however, let medical and pharmacy teams work from the same facts instead of two incomplete pictures.
For employers facing renewal decisions, the central question is whether the pharmacy benefit is being managed in a system that can act on the full clinical record or one that can only see the drug claim. The difference shows up in adherence, prior authorization turnaround, emergency use, inpatient spending, and the number of members who end up in the high-cost category. The numbers in this material point in one direction: when claims data are connected, the plan can intervene earlier, and earlier intervention changes what the next claim looks like.